ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Scleroderma"

  • Abstract Number: 1066 • 2019 ACR/ARP Annual Meeting

    Dysregulated IL-6 Dependent Dermal Adenosine Signaling via Adenosine A2A Receptor May Drive Fibrosis in Systemic Sclerosis

    Christopher Denton 1, Shiwen Xu 2, Sue Verma 3 and Voon Ong4, 1University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, 2University College London, London, United Kingdom, 3Leadiant Biosciences, London, United Kingdom, 4UCL Medical School, Royal Free Campus, London

    Background/Purpose: Altered generation of adenosine from extracellular nucleotides by ectonucleotidases may orchestrate chronic injury responses and promote fibrosis via the adenosine A2A receptor (ADORA2A). We…
  • Abstract Number: 2590 • 2019 ACR/ARP Annual Meeting

    Computer Vision Applied to Dual Energy Computed Tomography Images for Precise Calcinosis Cutis Quantification in Patients with Systemic Sclerosis

    Anita Chandrasekaran1, Imran Omar 2, Zhicheng Fu 3, Shangping Ren 3 and Monique Hinchcliff 1, 1Yale University, Section of Rheumatology, Allergy and Immunology, New Haven, CT, 2Northwestern University Feinberg School of Medicine, Chicago, IL, 3San Diego State University, Department of Computer Science, San Diego, CA

    Background/Purpose: Calcinosis cutis, found in both systemic sclerosis (SSc) and juvenile dermatomyositis patients, can be extensive and debilitating. Potential treatments have been identified, but a…
  • Abstract Number: 728 • 2019 ACR/ARP Annual Meeting

    Nailfold Videocapillaroscopy Patterns and Digital Occlusive Arterial Disease on Laser Doppler Flowmetry Strongly Predicts the Diagnosis of Systemic Sclerosis and Other Connective Tissue Diseases

    Yasser Radwan1, Tina Gunderson 2, Cynthia Crowson 3, David Liedl 4, Alicia Hinze 1, Kenneth Warrington 4, Paul Wennberg 4 and Ashima Makol 1, 1Mayo Clinic Minnesota, rochester, MN, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic Rochester, Rochester, 4Mayo Clinic Rochester, rochester, MN

    Background/Purpose: Vasculopathy is a key feature of systemic sclerosis (SSc), a chronic autoimmune disease associated with widespread fibrosis and internal organ dysfunction. While structural abnormalities…
  • Abstract Number: 1069 • 2019 ACR/ARP Annual Meeting

    CD4+ T Helper Cell Populations with High PD-1 Expression Are Expanded in Systemic Sclerosis

    Alisa Mueller1, Andrea Fava 2, Deepak Rao 1 and Francesco Boin 3, 1Brigham and Women's Hospital, Boston, MA, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3UCSF, San Francisco, CA

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by tissue fibrosis, vascular injury, and autoantibody production. CXCR5+ PD-1+ T follicular helper (Tfh) cells, which…
  • Abstract Number: 2591 • 2019 ACR/ARP Annual Meeting

    Hospitalization Among Incident Cases of Systemic Sclerosis: Results from a Population-based Cohort (1980-2016)

    Caitrin Coffey1, Avneek Singh Sandhu 2, Cynthia Crowson 3, Sara Achenbach 1, Eric Matteson 4, Thomas Osborn 5, Kenneth Warrington 6 and Ashima Makol 5, 1Mayo Clinic, Rochester, MN, 2kettering health, dayton, OH, 3Mayo Clinic Rochester, Rochester, 4Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, 5Mayo Clinic Minnesota, rochester, MN, 6Mayo Clinic Rochester, Rochester, MN

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disorder associated with multi-organ dysfunction, requiring long-term and multi-disciplinary care. Few studies have estimated the healthcare resource usage…
  • Abstract Number: 729 • 2019 ACR/ARP Annual Meeting

    Modelled Patient Level Skin Score Trajectory Predicts Risk of Death or Major Organ-Based Complications in Diffuse Cutaneous Systemic Sclerosis

    Svetlana Nihtyanova1, Emma Derrett-Smith 1, Carmen Fonseca 1, Voon Ong 2 and Christopher Denton 3, 1UCL Medical School, Royal Free Campus, London, United Kingdom, 2UCL Medical School, Royal Free Campus, London, 3University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom

    Background/Purpose: For most patients with diffuse cutaneous systemic sclerosis (dcSSc), skin thickness improves over time, especially with background immunosuppressive treatment. This has reduced confidence in…
  • Abstract Number: 1628 • 2019 ACR/ARP Annual Meeting

    Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom

    Aryeh Fischer1, Oliver Distler 2, Dinesh Khanna 3, Yannick Allanore 4, Anna Maria Hoffmann-Vold 5, Gabriele Valentini 6, Toby Maher 7, Martin Aringer 8, Leslie Meng 9, Margarida Alves 10, Martina Gahlemann 11, Manuel Quaresma 10 and Masataka Kuwana 12, 1University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, 2Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, 3Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, 4Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, 5Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 6Dipartimento di Medicina di Precisione, II Policlinico U.O. Reumatologia, Napoli, Italy, Napoli, Italy, 7National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom, 8Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, 9Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, 10Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 11Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, 12Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan

    Background/Purpose: Interstitial lung disease (ILD) is a common and usually early manifestation of systemic sclerosis (SSc). Decline in lung function in patients with SSc-ILD is…
  • Abstract Number: 2595 • 2019 ACR/ARP Annual Meeting

    Asymptomatic Scleroderma Antibody Positivity and Progression to Systemic Sclerosis

    Derek Jones 1, Marissa Mangini 1, Sydney Wearing 1 and Victoria Shanmugam2, 1The George Washington University School of Medicine and Health Sciences, Washington, DC, 2George Washington University, Georgetown, DC

    Background/Purpose: Systemic sclerosis is an autoimmune disease characterized by inflammation, vasculopathy and fibrosis of the skin, vasculature and internal organs along with disease specific autoantibody…
  • Abstract Number: 730 • 2019 ACR/ARP Annual Meeting

    Energy Levels: An Overlooked Element in Patient Assessment in Scleroderma

    Yossra Suliman1, Suzanne Kafaja 2, Mohamed Alemam 3 and Daniel Furst 4, 1Rheumatology and Rehabilitation Department. Faculty of Medicine. Assiut University, Assiut, Egypt, 2Department of Medicine. Rheumatology Division. UCLA, Los Angeles, CA, 3Clinical Pathology and Chemistry Department. Qena Faculty of Medicine. South Valley University, Assiut, Egypt, 4University of California, Los Angeles, CA

    Background/Purpose: Scleroderma (SSc) is a debilitating multi-system chronic disease which directly affects patient related Quality of Life. We wanted to identify how the patient interprets…
  • Abstract Number: 1636 • 2019 ACR/ARP Annual Meeting

    Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial

    Maureen Mayes1, Kristin Highland 2, Martina Gahlemann 3, Aryeh Fischer 4, Ganesh Raghu 5, Mannaig Girard 6, Margarida Alves 7, Susanne Stowasser 7, Jörg Distler 8, Marco Matucci-Cerinic 9, Elizabeth Volkmann 10, Masataka Kuwana 11 and Oliver Distler 12, 1Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, 2Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, 3Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, 4University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, 5University of Washington, Seattle, USA, Seattle, 6Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, 7Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 8Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, 9University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, 10University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, 11Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, 12Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland

    Background/Purpose: The presence of anti-topoisomerase I antibody (ATA) in patients with systemic sclerosis (SSc) has been associated with a greater risk of developing interstitial lung…
  • Abstract Number: 2607 • 2019 ACR/ARP Annual Meeting

    Ultrasound Detection of Calcinosis and Correlation with Ulnar Artery Occlusion in Patients with Systemic Sclerosis

    Robert Fairchild1, Melody Chung 1, Laurel Sharpless 1, Shufeng Li 2 and Lorinda Chung 1, 1Stanford University, Palo Alto, CA, 2Division of Immunology and Rheumatology, Department of Medicine, Stanford, Palo Alto, CA

    Background/Purpose: Systemic Sclerosis (SSc) is a progressive fibrotic and vascular disease affecting multiple organs. Calcinosis cutis in SSc is characterized by calcium deposition in the…
  • Abstract Number: 1741 • 2018 ACR/ARHP Annual Meeting

    Disease Duration and Autoantibodies Predict Distinct Skin Score Trajectories in Diffuse Cutaneous Systemic Sclerosis

    Svetlana I. Nihtyanova1, Alper Sari2, Voon H. Ong3 and Christopher P. Denton4, 1Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, 2Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 3Division of Medicine, University College London, London, United Kingdom, 4University College London, London, United Kingdom

    Background/Purpose: Although severity of skin involvement and change in skin thickness over time vary substantially between patients with diffuse cutaneous systemic sclerosis (dcSSc), for the…
  • Abstract Number: 1820 • 2018 ACR/ARHP Annual Meeting

    Myeloablative Autologous Hematopoietic Stem Cell Transplantation for Severe Scleroderma: Long-Term Outcomes 6-11 Years after Entry on a Randomized Study Comparing Transplantation and Cyclophosphamide

    Keith Sullivan1, Ashley Pinckney2, Ellen Goldmuntz3, Beverly Welch4, Dinesh Khanna5, Robert W. Simms6, Suzanne Kafaja7, George Georges8, Jan Storek9, Mary Ellen Csuka10, Richard Nash11, Daniel E. Furst12, Leslie Crofford13, Peter McSweeney11, Maureen D. Mayes14 and Lynette Keyes-Elstein15, 1Duke University Medical Center, Durham, NC, 2Rho Federal Systems, Inc., Chapel Hill, NC, 3NIAID, NIH, Bethesda, MD, 4National Institutes of Health, Bethesda, MD, 5Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, 6Rheumatology, Boston University School of Medicine, Boston, MA, 7David Geffen School of Medicine, UCLA, Los Angeles, CA, 8Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, 9University of Calgary, Calgary, AB, Canada, 10Medicine, Medical College of Wisconsin, Milwaukee, WI, 11Colorado Blood Cancer Institute, Denver, CO, 12University of Washington, Seattle, WA, 13Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, 14Rheumatology, University of Texas McGovern Medical School, Houston, TX, 15Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC

    Background/Purpose: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial demonstrated that for adults with severe scleroderma (ACR 1995 criteria) and internal organ involvement, myeloablative CD34+selected autologous…
  • Abstract Number: 2701 • 2018 ACR/ARHP Annual Meeting

    Botulinum Toxin in the Management of Raynaud’s Phenomenon

    Daniel Ennis1,2, Zareen Ahmad3, Keshini Devakandan1, Melanie A Anderson4 and Sindhu Johnson1, 1Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2Rheumatology, University of British Columbia, Vancouver, BC, Canada, 3Toronto Scleroderma Program, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 4University Health Network Library Services, Toronto General Hospital, Toronto, ON, Canada

    Background/Purpose: The objectives of this study were to evaluate the effectiveness and safety of botulinum toxin injection in Raynaud’s phenomenon. Methods: Medline and Embase databases…
  • Abstract Number: 2708 • 2018 ACR/ARHP Annual Meeting

    Current Management of Early Diffuse Cutaneous Systemic Sclerosis in US Scleroderma Centers

    Rebecca B. Blank1, Jessica K. Gordon2, Jackie Szymonifka3, Shervin Assassi4, Elana J. Bernstein5, Flavia V. Castelino6, Robyn T. Domsic7, Faye N. Hant8, Monique Hinchcliff9, Kate Homer10, Ami A. Shah11, Victoria Shanmugam12, Virginia D. Steen13, Tracy M. Frech14 and Dinesh Khanna15, 1Internal Medicine, New York Presbyterian-Weill Cornell Hospital, New York, NY, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Hospital for Special Surgery, New York, NY, 4University of Texas McGovern Medical School, Houston, TX, 5Rheumatology, Columbia University, New York, NY, 6Rheumatology, Harvard Medical School, Boston, MA, 7Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 8Rheumatology, Medical University of South Carolina, Charleston, SC, 9Division of Rheumatology, Northwestern University Medical School, Chicago, IL, 10Department of Internal Medicine, Rheumatology Division, Scleroderma Program, University of Michigan, Ann Arbor, MI, 11Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 12Rheumatology, The George Washington University, Washington, DC, 13Rheumatology, MedStar Georgetown University Hospital, Washington, DC, 14Division of Rheumatology, University of Utah, Salt Lake City, UT, 15Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI

    Background/Purpose: Standard treatment for the diverse aspects of diffuse cutaneous systemic sclerosis (dcSSc) is not yet well defined although experts have described therapeutic algorithms.  The…
  • « Previous Page
  • 1
  • …
  • 27
  • 28
  • 29
  • 30
  • 31
  • …
  • 33
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology